To the editor:

We read with great interest the article by Hedge et al,1  reporting that Δ12-prostaglandin (PG) J312-PGJ3) has antileukemic activity in mice. Anti-inflammatory and antineoplastic activity has also been reported for 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2).2  We agree with Hedge et al1  that one of the most important questions is whether sufficient quantities of Δ12-PGJ3 are formed in vivo to exert any biologic activity. Here, we comment on this eminently crucial issue from pharmacologic and nutrition perspectives.

PGJ3 and PGJ2 are the dehydrated products of PGD3 and PGD2 formed in vivo from eicosapentaenoic acid (EPA) and arachidonic acid (ARA), respectively, by the catalytic action of cyclooxygenase (COX). PGJ3 and PGJ2 are further dehydrated and isomerized to produce Δ12-PGJ3 and 15d-PGJ3 and 5d-PGJ2, respectively. Common feature of Δ12-PGJ3 and 15d-PGJ2 is the highly reactive cyclopentenone ring, which is readily attacked by low- and high-molecular-mass thiols to form thioethers (Figure 1). Thiolation of Δ12-PGJ3 and 15d-PGJ2 is likely to reduce both availability and bioactivity of Δ12-PGJ3 and 15d-PGJ2. So far, there are no data about excretion of Δ12-PGJ3 and 15d-PGJ3. We (Figure 1) and others3  found only pM-concentrations of 15d-PGJ2 in human urine, while PGJ3 metabolites including 15d-PGJ3 were below the detection limit of our method (30 pM) in urine. This may suggest that basal PGJ3 biosynthesis from EPA is several fold lower than PGJ2 from ARA. Dietary EPA has been shown to increase formation of prostaglandin I3 (PGI3) and thromboxane A3 (TxA3), but EPA, even at very high doses, did not increase PGI3 and TxA3 synthesis to a degree comparable with that of PGI2 and TxA2 from ARA.4 

Figure 1

Excretion of 15d-PGJ2 in human urine and its in vitro conjugation with glutathione, L-cysteine and N-acetylcysteine. (A) Reaction of 30μM 15d-PGJ2 with each 1110μM glutathione (GSH), L-cysteine (Cys) or N-acetylcysteine (NAC) in 100mM phosphate buffer (pH 7.4) resulted in formation of the corresponding conjugates and concomitant decrease of 15d-PGJ2 as measured by high-performance liquid chromatography (HPLC). Retention time was 12.7, 3.6, 2.8 and 1.2 minutes for 15d-PGJ2 and the 15d-PGJ2-NAC, 15d-PGJ2-Cys, and 15d-PGJ2-GSH conjugates, respectively. Reaction of 15d-PGJ2 with Cys was accompanied by a shift of the maximum wavelength from 318 nm to 312 nm and an increase in absorbance at 230 nm. (B,C) The HPLC fractions of the above mentioned conjugates were collected and subjected to catalytical hydrogenation/desulfurization as described elsewhere for the cysteinyl leukotriene E4.5  After derivatization with pentafluorobenzyl (PFB) bromide (PFB-Br) followed by N-methyl-N-trimethylsilyl-trifluoroacetamide (MTSFA) in the presence of NH4I and 2-mercaptoethanol (ME), gas chromatography-mass spectrometry (GC-MS) spectra were generated in the electron-capture negative-ion chemical ionization mode (B). The precursor ion at m/z 397 [M-PFB] was subjected to collision-induced dissociation (CID) to generate GC-tandem MS (GC-MS/MS) spectra (C). Expectedly, virtually identical GC-MS and GC-MS/MS mass spectra were obtained from all thiol (RSH) conjugates of 15d-PGJ2. Inserts in panels B and C indicate schematically part of the analytical procedure used and the proposed structures for the ions obtained. (D) Excretion of 15d-PGJ2 and the isoprostane 15(S)-8-iso-PGF (iso-PGF) was measured in fresh spot urine samples of 12 healthy volunteers (4 females) by GC-MS/MS using 2H4-15d-PGJ2 and 2H4-15(S)-8-iso-PGF as internal standards. 15(S)-8-iso-PGF was extracted from urine (1 mL) by immunoaffinity column chromatography.6  15d-PGJ2 was extracted from acidified (pH 4.5) urine samples by solid-phase extraction and purified by isocratic reverse phase HPLC. In the urine samples no 15d-PGJ3 was detectable. 15(S)-8-iso-PGF was measured because it is considered a COX-independent metabolite, analogous to 15d-PGJ2 and 15d-PGJ3.

Figure 1

Excretion of 15d-PGJ2 in human urine and its in vitro conjugation with glutathione, L-cysteine and N-acetylcysteine. (A) Reaction of 30μM 15d-PGJ2 with each 1110μM glutathione (GSH), L-cysteine (Cys) or N-acetylcysteine (NAC) in 100mM phosphate buffer (pH 7.4) resulted in formation of the corresponding conjugates and concomitant decrease of 15d-PGJ2 as measured by high-performance liquid chromatography (HPLC). Retention time was 12.7, 3.6, 2.8 and 1.2 minutes for 15d-PGJ2 and the 15d-PGJ2-NAC, 15d-PGJ2-Cys, and 15d-PGJ2-GSH conjugates, respectively. Reaction of 15d-PGJ2 with Cys was accompanied by a shift of the maximum wavelength from 318 nm to 312 nm and an increase in absorbance at 230 nm. (B,C) The HPLC fractions of the above mentioned conjugates were collected and subjected to catalytical hydrogenation/desulfurization as described elsewhere for the cysteinyl leukotriene E4.5  After derivatization with pentafluorobenzyl (PFB) bromide (PFB-Br) followed by N-methyl-N-trimethylsilyl-trifluoroacetamide (MTSFA) in the presence of NH4I and 2-mercaptoethanol (ME), gas chromatography-mass spectrometry (GC-MS) spectra were generated in the electron-capture negative-ion chemical ionization mode (B). The precursor ion at m/z 397 [M-PFB] was subjected to collision-induced dissociation (CID) to generate GC-tandem MS (GC-MS/MS) spectra (C). Expectedly, virtually identical GC-MS and GC-MS/MS mass spectra were obtained from all thiol (RSH) conjugates of 15d-PGJ2. Inserts in panels B and C indicate schematically part of the analytical procedure used and the proposed structures for the ions obtained. (D) Excretion of 15d-PGJ2 and the isoprostane 15(S)-8-iso-PGF (iso-PGF) was measured in fresh spot urine samples of 12 healthy volunteers (4 females) by GC-MS/MS using 2H4-15d-PGJ2 and 2H4-15(S)-8-iso-PGF as internal standards. 15(S)-8-iso-PGF was extracted from urine (1 mL) by immunoaffinity column chromatography.6  15d-PGJ2 was extracted from acidified (pH 4.5) urine samples by solid-phase extraction and purified by isocratic reverse phase HPLC. In the urine samples no 15d-PGJ3 was detectable. 15(S)-8-iso-PGF was measured because it is considered a COX-independent metabolite, analogous to 15d-PGJ2 and 15d-PGJ3.

Close modal

Δ12-PGJ3 and 15d-PGJ2 are considered potentially useful therapeutic agents for the treatment of cancer.1,2  Dietary EPA supplementation is unlikely to produce nM-concentrations of Δ12-PGJ3 required for antileukemic activity, but topical administration of considerable amounts of synthetic Δ12-PGJ3 would be required.

Acknowledgments: The authors thank B. Beckmann, K. Berg, A. Mitschke and M.-T. Suchy for laboratory assistance and Frank-Mathias Gutzki for performing GC-MS/MS analyses.

Contribution: D.T. and D.O.S designed and performed the study, analyzed the data, and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Prof Dimitrios Tsikas, Institute of Clinical Pharmacology, Hannover Medical School, Carl-Neuberg-Str 1, 30625 Hannover, Germany; e-mail: [email protected].

1
Hegde
 
S
Kaushal
 
N
Ravindra
 
KC
et al. 
Delta12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice.
Blood
2011
, vol. 
118
 
26
(pg. 
6909
-
6919
)
2
Pacienza
 
N
D'Atri
 
LP
Pozner
 
RG
et al. 
15-deoxy-delta12,14-PGJ2, induces cell cycle arrest and apoptosis of haematopoietic progenitors.
Br J Haematol
2010
, vol. 
148
 
1
(pg. 
173
-
175
)
3
Bell-Parikh
 
LC
Ide
 
T
Lawson
 
JA
et al. 
Biosynthesis of 15-deoxy-delta12,14-PGJ2, and the ligation of PPARγ.
J Clin Invest
2003
, vol. 
112
 
6
(pg. 
945
-
955
)
4
Abeywardena
 
MY
Fischer
 
S
Schweer
 
H
et al. 
In vivo formation of metabolites of prostaglandins I2 and I3 in the marmoset monkey (Callithrix jacchus) following dietary supplementation with tuna fish oil.
Biochim Biophys Acta
1989
, vol. 
1003
 
2
(pg. 
161
-
166
)
5
Tsikas
 
D
Fauler
 
J
Gutzki
 
FM
et al. 
Gas chromatographic-mass spectrometric determination of leukotriene E4 in human urine using deuterium-labeled leukotriene E4 standards.
J Chromatogr
1993
, vol. 
622
 
1
(pg. 
1
-
7
)
6
Tsikas
 
D
Schwedhelm
 
E
Suchy
 
MT
et al. 
Divergence in urinary 8-iso-PGF(2alpha) (iPF(2alpha)-III, 15-F(2t)-IsoP) levels from gas chromatography-tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF(2alpha). Possible methodological, mechanistic and clinical implications.
J Chromatogr B Analyt Technol Biomed Life Sci
2003
, vol. 
794
 
2
(pg. 
237
-
255
)
Sign in via your Institution